Prophylactic High-Dose rhEPO No Benefit for Preemies

This article originally appeared here.
Share this content:
Prophylactic High-Dose rhEPO No Benefit for Preemies
Prophylactic High-Dose rhEPO No Benefit for Preemies

WEDNESDAY, May 18, 2016 (HealthDay News) -- Prophylactic early high-dose recombinant human erythropoietin (rhEPO) given intravenously to very preterm infants does not improve neurodevelopmental outcomes at 2 years corrected age, according to a study published in the May 17 issue of the Journal of the American Medical Association.

Giancarlo Natalucci, M.D., from the University of Zurich, and colleagues randomized preterm infants born between 26 weeks 0 days and 31 weeks 6 days of gestation to receive rhEPO (228 infants) or placebo (220 infants) intravenously after birth. The authors assessed cognitive development with the Mental Development Index (MDI) at 2 years corrected age as the primary outcome.

The researchers found that at a mean age of 23.6 months, neurodevelopmental outcome data were available for 81 percent of infants. The mean MDI was not statistically significantly different between the rhEPO and placebo groups (93.5 versus 94.5; P = 0.56) The groups did not differ in terms of secondary outcomes.

"Among very preterm infants who received prophylactic early high-dose rhEPO for neuroprotection, compared with infants who received placebo, there were no statistically significant differences in neurodevelopmental outcomes at 2 years," the authors write. "Follow-up for cognitive and physical problems that may not become evident until later in life is required."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »